About temsirolimus
mTOR kinase inhibitor
Used for
- Treatment of advanced renal cell carcinoma in adults.
Usual adult dose
25 mg by intravenous infusion once weekly; dose may be adjusted for side effects.
Common side effects
- Rash, nausea, diarrhea, and reduced appetite
- Infections and low blood cell counts
- High blood sugar or cholesterol
- Lung inflammation, which can cause cough or breathlessness
Important warnings
- Infusion reactions can be serious; monitoring during treatment is needed.
- May increase infection risk and impair wound healing.
- Can cause lung inflammation, kidney problems, or high blood sugar.
- Avoid live vaccines; fetal harm is possible.
Pregnancy
May harm an unborn baby. Effective contraception is recommended during treatment and for 3 months after the last dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for 3 weeks after the last dose.
Interactions
- Strong CYP3A4 inhibitors can raise temsirolimus levels.
- Strong CYP3A4 inducers can lower temsirolimus levels.
- May affect warfarin and other medicines processed by CYP3A enzymes.
- Grapefruit may alter drug levels; avoid unless a clinician confirms it is safe.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.